Most Read Articles
22 hours ago
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
2 days ago
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.
Yesterday
Middle-aged Caucasian men who are dissatisfied with their marriage are at higher risk of sudden cardiac death regardless of other cardiovascular risk factors, a new study reports.

Ranolazine does not lower incidence of first VT/VF, death in high-risk ICD patients

09 Aug 2018
The implantable cardioverter defibrillator (ICD) is a small device implanted under the skin in the chest, to help control life-threatening arrhythmias.

Ranolazine has failed to significantly reduce the incidence of the first ventricular tachycardia (VT) or ventricular fibrillation (VF) or death in high-risk patients with implantable cardioverter-defibrillators (ICDs), a recent study has found. However, this study is underpowered to detect a difference in the primary endpoint.

Moreover, prespecified secondary endpoint analyses reveal an association between ranolazine administration and a significant reduction in recurrent VT or VF requiring ICD therapy without evidence for increased mortality.

This double-blind, placebo-controlled clinical trial randomized high-risk ICD patients with ischaemic or nonischaemic cardiomyopathy to 1,000-mg ranolazine twice a day or placebo. VT or VF requiring appropriate ICD therapy or death, whichever occurred first, was the primary endpoint. Prespecified secondary endpoints included ICD shock for VT, VR or death and current VT or VR requiring ICD therapy.

A total of 1,012 ICD patients (mean age 64 years; 18 percent women) were included in the trial (ranolazine, n=510; placebo, n=502). The primary endpoint occurred in 372 (37 percent) patients during 28 months of follow-up. There were 270 (27 percent) VT or VF cases and 148 (15 percent) deaths.

A total of 199 (39.6 percent) patients receiving placebo and 253 (49.6 percent) patients on ranolazine discontinued treatment (p=0.001). The hazard ratio (HR) for VT, VF or death with ranolazine vs placebo was 0.84 (95 percent CI, 0.67–1.05; p=0.117).

Based on a prespecified secondary analysis, patients on ranolazine had a marginally significant lower risk of ICD therapies for recurrent VT or VF (HR, 0.70; 0.51–0.96; p=0.028). No other significant treatment effects were noted in other prespecified secondary analyses, including components of the primary endpoint, inappropriate shocks, cardiac hospitalizations and quality of life.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 hours ago
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
2 days ago
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.
Yesterday
Middle-aged Caucasian men who are dissatisfied with their marriage are at higher risk of sudden cardiac death regardless of other cardiovascular risk factors, a new study reports.